Profile for Denmark Patent: 2015754
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Denmark Patent: 2015754
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 9,173,859 | May 4, 2027 | Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin |
| 8,673,927 | Nov 4, 2027 | Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride |
| 8,673,927 | Nov 4, 2027 | Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin |
| 8,673,927 | Nov 4, 2027 | Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride |
| 8,673,927 | Nov 4, 2027 | Boehringer Ingelheim | TRADJENTA | linagliptin |
| 9,173,859 | Nov 4, 2027 | Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
